Iron Deficiency Anemia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Iron Deficiency Anemia – Drugs In Development, 2024 report and make more profitable business decisions.
Anemia is a condition in which the body does not have enough healthy red blood cells. Iron helps make red blood cell; when the body does not have enough iron, it will make fewer red blood cells or red blood cells that are too small. This is called iron deficiency anemia. Symptoms include feeling grumpy, headaches, and problems concentrating or thinking. Treatment includes iron supplements and eating iron-rich foods.
The Iron Deficiency Anemia drugs in development market research report provide comprehensive information on the therapeutics under development for Iron Deficiency Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Iron Deficiency Anemia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Iron Deficiency Anemia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 20 molecules, with 19 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Iron Deficiency Anemia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Iron Deficiency Anemia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Iron Deficiency Anemia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Akebia Therapeutics IncDana-Farber Cancer Institute Inc
Disc Medicine Inc
Drogsan Pharmaceuticals
Entrinsic Bioscience Inc
Iron4u Aps
Jiangsu Aosaikang Pharmaceutical Co Ltd
Keros Therapeutics Inc
Keylika Inc
Korea Pharma Co Ltd
KYE Pharmaceuticals Inc
Nemysis Ltd
Novartis AG
Pharmacosmos AS
Regeneron Pharmaceuticals Inc
Renibus Therapeutics Inc
Rockwell Medical Inc
Shield Therapeutics Plc
Sun Pharmaceutical Industries Ltd
Viramal Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Iron Deficiency Anemia reports